VSPharmTech (VSPT) is a clinical-stage biotechnology company developing anticancer drugs for the paradigm shift in cancer treatment since 2018. It is committed to paradigm shift in the development of radiosensitizers by offering a mechanism-driven synergy-equipped radiosensitizer that excels in low toxicity, thus enabling its application across various types of tumors.
VSPT has succeeded in FDA approval for Phase 2 clinical trial in head and neck cancer and breast cancer in 2023 and in 2024, earning international recognition. VSPT has been cooperating with MD Anderson Cancer Center to operate clinical trials while communicating with Johnson & Johnson (J&J) through the JLABS, which is an incubation program operated by J&J, which has already engaged in research of radiosensitizers.

VS-101 is a radiosensitizer designed to enhance the effectiveness of radiotherapy. It has received Phase 2 IND approval from the FDA for the treatment of head and neck cancer and breast cancer. By improving therapeutic outcomes while maintaining low toxicity, VS-101 is expected to enhance the quality of life for patients undergoing radiotherapy.